In terms of immunotherapy, no response was observed in two cases with NSCLC, the efficacy of ICIs in patients with NTRK fusion has not been well described, and whether combination of TRK inhibitors with ICIs possesses better efficacy and safety is not yet clear, thus, further investigation is urgently required to address these issues more fully. Here, NTRK1 is linked to non-small cell lung carcinoma.